

Page 1 of 6



VIYASH LIFE SCIENCES PRIVATE LIMITED

PHARMACEUTICALS IN THE ENVIRONMENT/ AMR POLICY

Doc No. VLPL / PIE-AMR /001

Issue No: 1.0

Effective Date: 03-11-2023

	Approved by	
Signature &Date	A. David of	11/2023
Name	Dr B. Hari Babu	
Designation	CEO	



Page 2 of 6

Contents

1.	1. Introduction		3
	0	Pharmaceuticals in the Environment	
	0	Our Mission	
	0	Our Position	
2.	Our A	Approach	4
	0	Environmental Understanding	
	0	Risk Mitigation and Minimization	
	0	Manufacturing	
	0	Safe Disposal	
	0	Compliance and Advocacy	(4)
	0	Continuous Improvement	
3.	Antin	nicrobial Resistance (AMR)	5
	0	Introduction to AMR	
	0	Critical Strategies to Address AMR Globally	
	0	Our Commitment to Addressing AMR	





Pharmaceuticals in the Environment

Viyash is driven by a powerful mission: to enhance and prolong human lives through continuous exploration and breakthroughs in science-based innovation. By leveraging these advancements, Viyash is dedicated to achieving better patient outcomes and meeting the ever-changing healthcare needs of society.

It is important to acknowledge that while medical therapies have significantly improved patients' well-being, they can inadvertently lead to the presence of pharmaceutical substances in sewer systems, which may eventually find their way into the aquatic environment. Recent research confirms this concern. However, based on our current understanding, the levels of active pharmaceutical ingredients detected in drinking water are not believed to pose a significant risk to human health.

Nonetheless, the impact on aquatic wildlife remains an area of active investigation. Viyash is committed to carefully analysing and evaluating the implications of these substances on the delicate balance of aquatic ecosystems. This responsible approach ensures that our dedication to enhancing human lives is complemented by a consideration of the broader environmental implications.

Our Position:

- Viyash is committed to minimizing the environmental impact of its activities and products throughout their lifecycle.
- We actively support and advocate for the societal and environmental values and encourage our suppliers and third parties to adopt these principles as well.
- Embracing state-of-the-art technologies whenever possible, we ensure the proper and legal disposal of waste containing active pharmaceutical ingredients, demonstrating our responsible approach to environmental stewardship.





Our Approach:

Viyash adopts a comprehensive approach that encompasses all aspects of our operations, including research and development (R&D), production, marketing, and pharmaceutical product disposal. This approach is designed to both understand and mitigate the potential impact of pharmaceuticals on the environment. Our commitment to environmental stewardship is reflected in the following key elements:

- 1. **Environmental Understanding:** Viyash places a high priority on gaining a deep understanding of the environmental implications of our pharmaceutical products. We invest in research and data analysis to identify potential environmental risks associated with our operations.
- 2. **Risk Mitigation and Minimization:** Armed with valuable insights, we proactively develop strategies to mitigate and minimize the identified risks. This involves implementing stringent controls and procedures throughout the entire lifecycle of our products.
- 3. **Manufacturing:** Viyash takes measures to minimize the release of active pharmaceutical ingredients into the aqueous environment. Ongoing monitoring allows us to identify and address potential emissions promptly. We collaborate with suppliers to ensure they adhere to our principles.
- 4. Safe disposal: Waste containing active pharmaceutical ingredients is never disposed of in landfills. We urge patients and consumers to follow applicable legal and regulatory requirements, as well as disposal instructions in patient information materials, for any unused or expired products or waste materials.
- 5. **Compliance and Advocacy:** Viyash is unwavering in its dedication to compliance with all relevant environmental regulations and guidelines. We also actively advocate for environmental responsibility and encourage our industry partners to adopt sustainable practices.
- 6. **Continuous Improvement:** Our commitment to environmental conservation is an ongoing journey. We constantly seek opportunities for improvement, welcoming advancements in technology and best practices to further enhance our environmental performance.





Antimicrobial resistance (AMR)

Antimicrobial resistance (AMR) stands as a pivotal scientific, health, and economic challenge, shaping our time and the foreseeable future. The gravity of the situation demands immediate and purposeful action, as failure to address specific diseases and systemic issues could expose patients, families, and communities worldwide to an unprecedented and insurmountable threat of untreatable infections. AMR's emergence is predominantly attributed to the inappropriate use and excessive utilization of antimicrobials, leading to the evolution of resilient pathogen strains. However, the ramifications of AMR transcend these factors, extending across various domains such as economics, healthcare, and agriculture, further exacerbating its impact.

The multifaceted nature of AMR and its far-reaching consequences necessitate a collaborative approach involving stakeholders from various sectors, including government, industry, society, and academia. By uniting under a shared agenda to combat AMR, we acknowledge the ambitious nature of our goal but draw inspiration from the successes achieved through global efforts against health challenges like HIV, TB, and polio eradication. These past achievements serve as a testament that progress is attainable when we work together.

In tackling AMR, our collective endeavour must focus on enhancing infection prevention, optimizing the deployment and delivery of existing tools across all nations, and driving the development of innovative solutions. By fostering cooperation and synergy among diverse stakeholders, we can forge a path forward that strengthens global health security and safeguards the well-being of people worldwide.

Critical Strategies to Address AMR Globally:

 Preventing Resistant Infections: Raising broad awareness and implementing education initiatives are essential for infection prevention. Vaccines play a pivotal role in minimizing AMR-relevant infectious diseases by reducing drug-sensitive and possibly resistant infections, antimicrobial use, and transmission of resistant microbial genes. Tailored

Page 6 of 6



Pharmaceuticals in the Environment / AMR Policy

prevention strategies based on local contexts are also necessary, with a focus on preventing healthcare-associated infections (HAIs) that contribute significantly to AMR-related infections in regions like the United States and Europe.

- Treating AMR Infections: Ensuring optimal recovery for patients with AMR-related infections involves preserving and extending the effectiveness of current therapies. This requires appropriate and judicious use of therapeutics in both humans and animals. Surveillance to track resistant pathogen prevalence, therapy effectiveness, and utilization is crucial. Effective health systems are essential for prompt diagnosis, tracking, and treatment of AMR-related infections.
- Discovering and Stewarding New Tools: Ongoing innovation and research efforts are vital to counter the growing drug resistance trend. Proper stewardship of antibiotic use is critical to prevent further resistance development. Tailored incentives are necessary to promote innovation and R&D investment in the unique antibiotics market. New diagnostics play a key role in limiting antimicrobial use to appropriate infections. Additionally, stewardship efforts ensure safe and correct antibiotic usage, safeguarding their long-term effectiveness.

Our Commitment:

• At Viyash, we actively contribute to addressing the AMR challenge, aiming to be a significant part of the solution. With unwavering determination, we have directed our efforts across all aspects of our business to tackle this critical issue head-on. Our commitment extends beyond our company's borders as we collaborate with partners worldwide, advocating for a sustainable ecosystem of innovation in the fight against AMR.

By working together with stakeholders, experts, and communities, we strive to drive positive change and make a lasting impact on the global battle against antimicrobial resistance. Through innovation, research, and responsible practices, we are dedicated to safeguarding public health and ensuring a better, healthier future for generations to come.